2021
Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings from the EXTEND-DAPT Study
Butala NM, Faridi KF, Tamez H, Strom JB, Song Y, Shen C, Secemsky EA, Mauri L, Kereiakes DJ, Curtis JP, Gibson CM, Yeh RW. Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings from the EXTEND-DAPT Study. Circulation 2021, 145: 97-106. PMID: 34743530, PMCID: PMC8748407, DOI: 10.1161/circulationaha.121.056878.Peer-Reviewed Original ResearchConceptsContemporary clinical practiceStent-treated patientsPercutaneous coronary interventionDAPT studyProlonged DAPTClinical practiceCoronary interventionMyocardial infarctionNational Cardiovascular Data Registry CathPCI RegistryTreatment effectsTrial resultsAttenuation of benefitLonger-duration DAPTMonths of DAPTProlonged DAPT durationDrug-eluting stentsCoronary stent proceduresModern clinical practiceGreater bleedingMore comorbiditiesRegistry patientsAntiplatelet therapyCerebrovascular eventsDAPT durationMore contemporary cohortsTrends in end-of- life (EOL) systemic oncologic treatment in contemporary clinical practice: Insights from real-world data.
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Trends in end-of- life (EOL) systemic oncologic treatment in contemporary clinical practice: Insights from real-world data. Journal Of Clinical Oncology 2021, 39: 253-253. DOI: 10.1200/jco.2020.39.28_suppl.253.Peer-Reviewed Original ResearchDay of deathReal-world practiceTraditional chemotherapyCancer treatmentStudy periodPractice-level factorsOverall healthcare utilizationSystemic cancer treatmentRates of chemotherapyDays of lifeDe-identified databaseContemporary clinical practiceLogistic regression modelsElectronic health recordsCancer care organizationsSystemic therapySystemic treatmentOncologic treatmentHealthcare utilizationImmune therapyTargeted therapyStratified analysisHigher total costsLife careOncolytic therapy
2020
Prevalence, treatment, and control of severe hyperlipidemia
Gold ME, Nanna MG, Doerfler SM, Schibler T, Wojdyla D, Peterson ED, Navar AM. Prevalence, treatment, and control of severe hyperlipidemia. American Journal Of Preventive Cardiology 2020, 3: 100079. PMID: 34327462, PMCID: PMC8315339, DOI: 10.1016/j.ajpc.2020.100079.Peer-Reviewed Original ResearchLDL-C controlHigh-intensity statinsLDL-C levelsLow-density lipoprotein cholesterol controlLDL-C treatment goalsPrior atherosclerotic cardiovascular diseaseMultivariable logistic regression modelingHealth systemDuke University Health SystemAtherosclerotic cardiovascular diseaseLDL-C measurementAfrican American raceCross-sectional prevalenceUniversity Health SystemUnited States adultsGreater reductionLogistic regression modelingContemporary clinical practiceIntensity statinsHigh LDLAppropriate therapyCholesterol controlSevere hyperlipidemiaFemale sexCardiovascular diseasePredictors of Cardiac Perforation With Catheter Ablation of Atrial Fibrillation
Friedman DJ, Pokorney SD, Ghanem A, Marcello S, Kalsekar I, Yadalam S, Akar JG, Freeman JV, Goldstein L, Khanna R, Piccini JP. Predictors of Cardiac Perforation With Catheter Ablation of Atrial Fibrillation. JACC Clinical Electrophysiology 2020, 6: 636-645. PMID: 32553212, DOI: 10.1016/j.jacep.2020.01.011.Peer-Reviewed Original ResearchConceptsPrevious cardiac surgeryCardiac perforationAF ablationIntracardiac echocardiographyCardiac surgeryFemale sexDiagnosis of hemopericardiumPatient risk factorsSubset of patientsAtrial fibrillation ablationContemporary clinical practiceIntraprocedural intracardiac echocardiographyLogistic regression modelsCardiac tamponadeFatal complicationProcedural complicationsRare complicationCatheter ablationFibrillation ablationAtrial fibrillationModifiable factorsRisk factorsProcedural safetyRisk scoreLower risk
2018
The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera
Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. Blood Advances 2018, 2: 2681-2690. PMID: 30333100, PMCID: PMC6199652, DOI: 10.1182/bloodadvances.2018021436.Peer-Reviewed Original ResearchConceptsRisk of thrombosisPV patientsOverall survivalThrombotic eventsMultivariable Cox proportional hazards modelsEnd Results-Medicare databaseHigh-risk PV patientsCox proportional hazards modelOlder adultsImpact of phlebotomyRetrospective cohort studyPopulation-based studyProportional hazards modelEffect of phlebotomyOutcomes of interestPolycythemia vera patientsContemporary clinical practiceImproved OSCohort studyCytoreductive therapyOlder patientsTherapeutic phlebotomyTreatment modalitiesCurrent guidelinesLower risk
2015
Use of outcome measures in pulmonary hypertension clinical trials
Parikh KS, Rajagopal S, Arges K, Ahmad T, Sivak J, Kaul P, Shah SH, Tapson V, Velazquez EJ, Douglas PS, Samad Z. Use of outcome measures in pulmonary hypertension clinical trials. American Heart Journal 2015, 170: 419-429.e3. PMID: 26385024, DOI: 10.1016/j.ahj.2015.06.010.Peer-Reviewed Original ResearchConceptsHypertension clinical trialsPulmonary arterial hypertensionPAH trialsClinical practiceInvasive hemodynamicsPrimary endpointClinical trialsOutcome measuresInvasive measuresSurrogate measureDuke University Medical CenterPatient-centered endpointsSecondary outcome measuresClinical treatment trialsMEDLINE/EMBASEUniversity Medical CenterSmall patient populationQuality of lifeContemporary clinical practicePAH therapyPH medicationsArterial hypertensionSerial echocardiographyPatient characteristicsSecondary outcomes
2007
Short- and Long-Term Outcomes After Stent-Assisted Percutaneous Treatment of Saphenous Vein Grafts in the Drug-Eluting Stent Era
Pucelikova T, Mehran R, Kirtane AJ, Kim YH, Fahy M, Weisz G, Lansky AJ, Moussa I, Gray WA, Collins MB, Kodali SK, Stone GW, Moses JW, Leon MB, Dangas G. Short- and Long-Term Outcomes After Stent-Assisted Percutaneous Treatment of Saphenous Vein Grafts in the Drug-Eluting Stent Era. The American Journal Of Cardiology 2007, 101: 63-68. PMID: 18157967, DOI: 10.1016/j.amjcard.2007.07.048.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCoronary AngiographyCoronary Artery BypassFemaleFollow-Up StudiesGraft Occlusion, VascularHumansMaleMultivariate AnalysisMyocardial InfarctionMyocardiumNecrosisPaclitaxelProspective StudiesProsthesis DesignRegistriesRetreatmentSaphenous VeinSirolimusStentsThrombosisConceptsMajor adverse cardiac eventsAdverse cardiac eventsPercutaneous coronary interventionDrug-eluting stentsSVG lesionsVessel revascularizationCardiac eventsCoronary interventionPercutaneous treatmentMyocardial infarctionStent-assisted percutaneous coronary interventionSaphenous vein graft lesionsNative vessel diseasePeriprocedural myocardial necrosisTarget lesion revascularizationTarget vessel revascularizationSaphenous vein graftsVein graft lesionsPresence of thrombusEmbolic protection devicesHigh-risk subgroupsLong-term outcomesContemporary clinical practiceLesion revascularizationStent thromboses
2002
Graduate Education and Training for Contemporary Behavioral Health Practice
Hoge MA, Jacobs S, Belitsky R, Migdole S. Graduate Education and Training for Contemporary Behavioral Health Practice. Administration And Policy In Mental Health And Mental Health Services Research 2002, 29: 335-357. PMID: 12238558, DOI: 10.1023/a:1019601106447.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply